Identification of Polymorphisms Involved in the Metabolism of Propofol

TC Erciyes University

Status and phase: Completed; Phase 4

Conditions: UGT1A1*28 Polymorphism

Treatments: Drug: propofol

Study type: Interventional

Funder types: Other

Identifiers

NCT02271542

2013/215

Details and patient eligibility

About

Identification of Polymorphisms Involved in the Metabolism of Propofol

Full description

Propofol inside and outside the operating room during anesthesia is a drug widely used. In terms of efficacy and side effect profile of propofol knows if properties are insufficient data on the metabolism. Propofol typically undergoes biotransformation by microsomal enzymes in the liver. For most of the administered dose, takes place glucuronidation by UGT1A9 enzyme, while the remaining portion is oxidized with CYP2B6 hydroxylation reactions. However, these enzymes are involved in the metabolism of propofol are enzymes highly polymorphic. Polymorphisms occurring in these enzymes; the effects of propofol, side effects and drug needs to show individual differences in terms of causes. Determination of the genetic background of individuals and personal anesthetic regimen improved. Thus, useful person drug resistance, increased incidence of side effects can be reduced. In particular, be aware of some mutations, such as propofol infusion syndrome mortal side effects can be prevented. The main purpose of this study, these individual differences are thought to be the cause of polymorphic variation in UGT1A9 and CYP2B6 gene to determine. Especially in the UGT1A9 gene mutations that may be associated with ethnic structure can be observed. In Caucasian, African-American communities and polymorphisms of this gene has been shown in Japanese. So all of them as a result of the genetic structure of any society can be considered as its own. Therefore, this study aimed to determine the genetic polymorphism of Turkish society has.Physiological factors such as age and sex between persons of different answers to the causes of propofol. Another object of this study was the identification of these factors can lead to different answers which is to present the relationship between polymorphisms.

Enrollment: 300 patients

Sex: All

Ages: 1 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who used propofol for induction onl
• Between the ages of 1-85

Exclusion criteria

• Patients taking drugs that may affect the metabolism of propofol (exp.Ketamine)
• Smoking and Alcohol users
• Patients using herbal medicines

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

300 participants in 3 patient groups

between 1-10 ages

Experimental group

Description:

Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.

Treatment:

Drug: propofol

under 60 ages

Experimental group

Description:

Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.

Treatment:

Drug: propofol

upper 60 ages

Experimental group

Description:

Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.

Treatment:

Drug: propofol